Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs
Direct Source Verification:
This story is aggregated from Forbes (forbes.com). Full reporting rights and copyright belong to the primary publisher.
Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.
For complete coverage, context, and related multimedia, visit the original reporting by Forbes via the source link below.
Original Source
https://www.forbes.com/sites/innovationrx/2026/10/28/why-an-ai-biotech-startup-launched-a-600-million-fund-to-buy-stalled-drugs/
